Yahoo Finance6d
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi
Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion for the expanded use of the ...
Pharmabiz5d
EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC
Janssen-Cilag International NV, a Johnson & Johnson company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...
JD Supra3d
EU Biosimilar Regulatory and Launch Updates
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted ...
Nasdaq6d
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
Please note that, in November 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) rendered a positive opinion recommending marketing approval for ...
Morningstar2d
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
In December 2024, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Omvoh for the treatment of adults with moderately to ...
Yahoo Finance3d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh ...
EuropaWire6d
AstraZeneca’s Imfinzi Recommended for EU Approval as Breakthrough Treatment for Limited-Stage Small Cell Lung Cancer
(PRESS RELEASE) CAMBRIDGE, 4-Feb-2025 — /EuropaWire/ — AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal ...
Malaysian Reserve3d
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
In December 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Omvoh for the treatment of adults with moderately to ...